Commonly Used Prognostic Tools Underestimate Survival for Melanoma Patients With Brain Metastases Treated With Radiosurgery in the Era of Immunotherapy and Targeted Agents
Daniel Gorovets(NYU Langone Health), Douglas Kondziolka(Neurological Surgery), Amparo Wolf(Western University), Anna C. Pavlick(Cornell University), Joshua S. Silverman(NYU Langone Health), Melissa Wilson(Massachusetts Institute of Technology), Shengyang Wu(Stanford University), S. Shin(NYU Langone Health), Naamit K. Gerber(New York University)
International Journal of Radiation Oncology*Biology*Physics
October 1, 2016
Cited by 2
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Role of experience and oscillations in transforming a rate code into a temporal code
|Nature|2002|657
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
|Journal of Neuro-Oncology|2009|514
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
|Nature Biotechnology|2005|238